More and more drug trials are being farmed out to contractors, but who's benefiting from the change? Meredith Wadman investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Can super-antibody drugs be tamed?
London's disastrous drug trial has serious side effects for research
Related external links
Rights and permissions
About this article
Cite this article
The quiet rise of the clinical contractor. Nature 441, 22–23 (2006). https://doi.org/10.1038/441022a
Published:
Issue Date:
DOI: https://doi.org/10.1038/441022a
This article is cited by
-
Effect of La2O3 modified on pyroelectric properties of 0.69Pb(Mg1/3Nb2/3)O3-0.31PbTiO3 solid solutions
Electronic Materials Letters (2012)
-
Trial blazers
Nature (2006)